FDA Clearance Tracker · K260827
Oncomine Dx Express Test
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this decision)Source: openFDAMethods & limitations
Decided
Oct 15, 2026
Substantially Equivalent
Time to decision
216 days
Received Mar 13, 2026. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K260827
- Device name
- Oncomine Dx Express Test
- Applicant
- Life Technologies Corporation
- Applicant location
- Frederick, MD
- Received
- Mar 13, 2026
- Decided
- Oct 15, 2026
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device type
- High Throughput Sequencing Based Tumor Profiling Test Of Circulating Cell-Free Nucleic Acids (SBY)
- Device class
- Class II
- Regulation
- 21 CFR 866.6085
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code SBY. The earliest in FDA's data is DEN230046, decided Aug 1, 2024.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K260827
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Life Technologies Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Oncomine Dx Express TestPMA supplement
P240040-S005 · Decided Sep 9, 2026 · 180 days after receipt · Panel Track
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
P240040 · Decided Jul 2, 2025 · 232 days after receipt
Device type: Next generation sequencing oncology panel, somatic or germline variant detection system (PQP) · Laboratory Medicine & Pathology
K241806 · Decided Jan 8, 2025 · 201 days after receipt
Device type: Multi-Target Respiratory Specimen Nucleic Acid Test Including Sars-Cov-2 And Other Microbial Agents (QOF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.